245 related articles for article (PubMed ID: 25250323)
1. Multiparametric MRI in the PSA screening era.
George AK; Pinto PA; Rais-Bahrami S
Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
[TBL] [Abstract][Full Text] [Related]
2. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
[TBL] [Abstract][Full Text] [Related]
3. [Current results on PSA-based prostate cancer detection].
Graefen M; Schlomm T; Steuber T; Sauter G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL.
Petrillo A; Fusco R; Setola SV; Ronza FM; Granata V; Petrillo M; Carone G; Sansone M; Franco R; Fulciniti F; Perdonà S
J Magn Reson Imaging; 2014 May; 39(5):1206-12. PubMed ID: 25006636
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.
Law KW; Nguyen DD; Barkin J; Zorn KC
Can J Urol; 2020 Feb; 27(27 Suppl 1):3-10. PubMed ID: 32101694
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
7. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer screening-current overview].
De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
Radiologie (Heidelb); 2024 Jun; 64(6):479-487. PubMed ID: 38743100
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
10. PSA testing beneficial for prostate cancer.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e424. PubMed ID: 25328952
[No Abstract] [Full Text] [Related]
11. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Duffy MJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
[TBL] [Abstract][Full Text] [Related]
12. MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer.
Peng Y; Shen D; Liao S; Turkbey B; Rais-Bahrami S; Wood B; Karademir I; Antic T; Yousef A; Jiang Y; Pinto PA; Choyke PL; Oto A
J Magn Reson Imaging; 2015 Dec; 42(6):1733-9. PubMed ID: 25946664
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.
Borofsky MS; Makarov DV
Nat Rev Urol; 2011 Jul; 8(8):413-4. PubMed ID: 21750502
[No Abstract] [Full Text] [Related]
14. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?
Abd-Alazeez M; Ahmed HU; Arya M; Charman SC; Anastasiadis E; Freeman A; Emberton M; Kirkham A
Urol Oncol; 2014 Jan; 32(1):45.e17-22. PubMed ID: 24055430
[TBL] [Abstract][Full Text] [Related]
15. [Multiparametric MRI for prostate cancer screening].
Hoeks CM; Fütterer JJ; Somford DM; van Oort IM; Huisman H; Barentsz JO
Ned Tijdschr Geneeskd; 2009; 153():B487. PubMed ID: 20003566
[TBL] [Abstract][Full Text] [Related]
16. The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: a meta-analysis.
Zhang ZX; Yang J; Zhang CZ; Li KA; Quan QM; Wang XF; Wang H; Zhang GX
Acad Radiol; 2014 May; 21(5):578-89. PubMed ID: 24703470
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MR Imaging for Detection and Locoregional Staging of Prostate Cancer.
Bittencourt LK; de Hollanda ES; de Oliveira RV
Top Magn Reson Imaging; 2016 Jun; 25(3):109-17. PubMed ID: 27187165
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnostic options for prostate cancer.
French WW; Wallen EM
Postgrad Med; 2020 Dec; 132(sup4):52-62. PubMed ID: 32900250
[TBL] [Abstract][Full Text] [Related]
19. [Prostate cancer - diagnostics and screening].
Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
[TBL] [Abstract][Full Text] [Related]
20. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
